Navigation Links
Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
Date:2/14/2012

d development

60.353.7227.7194.6Selling and marketing

42.531.0156.0111.9Segment contribution

$
417.5$
246.0$
,165.7$
833.0Segment margin

35.6%38.1%34.6%35.6%Adjusted gross profit (1)

$
513.7$
314.2$
,551.2$
,154.2Adjusted gross margin

43.8%50.6%46.2%49.9%(1) Adjusted gross profit represents adjusted net revenue less

adjusted cost of sales and excludes amortization of acquired

intangibles. Pro forma adjustments for the respective

periods include the following: Settlement of contingent asset acquired as part of a

business acquisition (other revenue)

$
-$
-$
(7.4)$
-Net revenue from payment received relating to

previously divested business

--(2.4)-Operational Excellence Initiative

1.28.59.430.3Purchase accounting adjustments

(7.8)-2.211.9Acquisition and licensing adjustments (other revenue)-(25.0)-(27.5)Global Generics net revenue for the fourth quarter 2011 increased 81 percent to $1.2 billion as a result of the launch of a generic version of Lipitor® in November and the launch of a generic version of Concerta® in May. Fourth quarter international net revenue was $151.9 million, up 2 percent from the fourth quarter 2010. International net revenue in the prior year period includes $25 million received from a development partner, which is excluded from our non-GAAP results. Excluding this amount, international net revenue increased 23 percent primarily as a result of the addition of Specifar Pharmaceuticals in May.

Global Generics R&D investment for the fourth quarter 2011 increased 12 percent to $60.3 million, primarily due to an increase of international R&D investment resulting from the addition of Specifar, and higher clinical development costs for  more complex products such as inhalation products, patches and gels.

For the full year 2011, Global Generics net reven
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Today, UBM China, a wholly owned subsidiary of ... Exhibition Co., Ltd. to jointly run the Health Expo ... concurrently with CWMEE 2016. This cooperation ... MEDTEC China and DENTECH China, and fills its blank ... also another concrete cooperative project in Chengdu ...
(Date:6/30/2015)... , June 30, 2015 ... ), a clinical-stage pharmaceutical Company focused on the development ... first patient has been screened in the Company,s Phase ... U.S. based study will be performed under the active ... U.S. Food and Drug Administration (FDA). The ...
(Date:6/30/2015)...  July 4 th is this weekend, a time ... and people behind it. To help honor our current nation,s ... USA Medical Card, a leading provider of free ... empower independence for our disabled military veterans, police, firemen, and ... their prescriptions. "Due to USA ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2
(Date:6/30/2015)... ... 2015 , ... iData Research ( http://www.idataresearch.com ), the leading ... policy tracking and analysis service. Reimbursement Tracker ™ enables medical device, dental, ... real-time from hundreds of insurance companies covering over 60,000 policies. , “Policy ...
(Date:6/30/2015)... Minn. (PRWEB) , ... June 30, 2015 , ... ... mobile-based nurse call and communications software, Notify™, for the senior care sector. As ... forefront of helping senior housing facilities to become more efficient and offer residents ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... D. Wagner, Chief Research and Strategy Officer at Predictive Analytics Reporting (PAR) Framework, ... National Science Foundation (NSF), will provide keynote addresses at the 2015 STEMtech conference ...
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up ... life. Back pain can range from a dull, constant ache (chronic) to a sudden ... epidural steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain ...
(Date:6/30/2015)... ... June 30, 2015 , ... Alice ... a 5-day tour in India. During her stay, she met with the ... Master Wellness™ and Transformational Leader/Internationally Beloved Spiritual Master Mahendra Trivedi to develop ...
Breaking Medicine News(10 mins):Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3
... have breast cancer are at increased risk of developing mood ... early online in Cancer , a peer-reviewed journal of ... address the mental health of cancer patients, loved ones. ... affected patients but of their closest relatives as well. Partners ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Sept. ... stove. You grab that hand with the other, and sometimes the ... their unusual study suggests that you can reset your brain,s image ... found that they were able to significantly decrease the levels of ...
... BOSTONIn the quest to arrest the growth and spread of ... to ignore their internal instruction manual. In a new ... created the first molecule able to prevent cancer genes from ... The study, published online by the journal Nature ...
... the growth and spread of tumors, there have been many ... manual. In a new study, a team led by ... to prevent cancer genes from "hearing" those instructions, stifling the ... by the journal Nature , demonstrates that proteins issuing ...
... cardiac care may begin almost as soon as patients ... published in Academic Emergency Medicine , Massachusetts General ... assessed for chest pain were less likely than white ... a lack of significant differences in symptoms. Such ...
... A new study looking at how hospitals account ... bloodstream infections (CA-BSIs) found substantial inconsistencies in the methods ... these infections. The study, conducted by the ... Intensive Care Unit Focus Group, appears in the October ...
Cached Medicine News:Health News:Partners of breast cancer patients are at risk of developing mood disorders 2Health News:'Self-Touch' May Reduce Pain, Study Finds 2Health News:'Self-Touch' May Reduce Pain, Study Finds 3Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 3Health News:Researchers create first molecule-blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule-blocks key component of cancer genes' on-off switch 3Health News:Disparities in heart attack treatment may begin in the emergency room 2Health News:Disparities in heart attack treatment may begin in the emergency room 3Health News:Study of bloodstream infections reveals inconsistent surveillance methods and reporting 2
Carl Zeiss immersion oils are PCF free. They are quality controlled for two wavelengths of light, Ne=1.518 and Nd=1.515 at 23ºC....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
... Oils are the standard - the ones to ... Laboratories has consistently led in the development and ... Here is the record: , When the FDA ... of In Vitro Diagnostics in the 1970's, Cargille ...
... an Informatics software product enabling quick and ... the laboratory. With SpecTRACK Software, users can ... specimen from all laboratories in their LAN ... or cold room. Automate your existing manual ...
Medicine Products: